Helius Medical Technologies, Inc. Presents Poster at the 2022 Consortium of Multiple Sclerosis Centers (“CMSC”) Annual Meeting
June 06 2022 - 7:05AM
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the
“Company”), a neurotech company focused on neurological wellness,
today announced that a poster detailing the benefits of the
Company’s Portable Neuromodulation Stimulator (“PoNS”) Therapy
combined with a therapeutic exercise program was presented at the
2022 Consortium of Multiple Sclerosis Centers (“CMSC”) Annual
Meeting held June 1-4, 2022, in National Harbor, Maryland.
“The CMSC Annual Meeting is a wonderful opportunity to engage
with thought leaders and researchers in the MS space. We are
delighted to share the benefits of our innovative PoNS device and
to be part of the community that is working to bring cutting edge
interventions to improve gait deficits in patients with MS. It is
especially gratifying that our poster was selected out of 150 to
receive a prestigious award nomination,” stated Antonella
Favit-VanPelt, MD, PhD, Chief Medical Officer of Helius.
“Importantly, this latest dataset provides key real-world
evidence of our therapy’s clinical benefits, which can be seen at
two weeks from beginning rehabilitation treatment with PoNS. We
look forward to continuing to gather real-world evidence through
our Therapeutic Experience Program (“TEP”), a multi-center,
company-sponsored, open label observational interventional trial to
evaluate the impact of subjects’ adherence to PoNS therapy for gait
improvement in MS, as well as through patients’ voluntary
participation to our upcoming registry program as part of the
recently announced Patient Therapy Access Program,” concluded Dr.
Favit-VanPelt.
Study Conclusions
- In this analysis of a real-world dataset of patients with MS
with generally long duration of disease, translingual
neurostimulation (PoNS Therapy) combined with a therapeutic
exercise program significantly improved gait deficit at Week 2, the
earliest evaluated time point, and at every subsequent time
point.
- Gait deficit was assessed by the Functional Gait Assessment
(“FGA”) scale. Mean improvements in FGA total scores based on
observed data were highly statistically significant at all
follow-up time points (paired t-test P<0.0001). Mean improvement
in FGA at Week 14 of PoNS therapy was 4.75 (95% CI: 3.66 to 5.84),
and the median improvement was 5 points with 58.3% of patients
showing an improvement of ≥4 points, noticeably greater than the
minimum detectable change (“MDC”) for older adults, stroke
patients, and persons with other neurological disease.
- Analysis of real-world data pooled with the two randomized
clinical trials (“RCTs”) demonstrated, consistent with the RCT
data, that PoNS Therapy is safe and effective in improving gait
deficit in individuals with mild and moderate symptoms from MS.
Mean improvement in the Dynamic Gait Index (DGI) assessment from
baseline to Week 14 was 4.58 (95% CI: 3.62 to 5.54) for the pooled
RWE and RCT analysis including all possible data at all weeks. Over
55% of patients treated with active PoNS therapy experienced ≥4
point-improvement from baseline in the DGI score.
Poster Details
Title: |
Translingual Neurostimulation by Portable Neuromodulation
Stimulator System as a New Rehabilitation Therapy for Improving
Gait in People With Multiple Sclerosis |
|
|
Authors: |
Antonella Favit-VanPelt, MD,
PhD1; Kim Skinner, PT, DPT1; Greg Maislin, PhD2; Nicole Strachan,
BHK, MSc. P.Kin1; and Lola Abhulimen, MBA1 |
|
|
ID: |
REH08 |
1Helius Medical Technologies, Newtown, PA.
2Biomedical Statistical Consulting, Wynnewood, PA.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotech company in
the medical device field focused on neurologic deficits using
non-implantable platform technologies that amplify the brain’s
ability to compensate and promotes neuroplasticity, aiming to
improve the lives of people dealing with neurologic diseases. The
Company’s first commercial product is the Portable Neuromodulation
Stimulator (PoNS). For more information, visit
www.heliusmedical.com.
About the PoNS Device and PoNS Therapy
The Portable Neuromodulation Stimulator (PoNS) is an innovative
non-surgical medical device, inclusive of a controller and
mouthpiece, which delivers electrical stimulation to the surface of
the tongue to improve balance and gait. The PoNS device is
indicated for use in the United States as a short-term treatment of
gait deficit due to mild-to-moderate symptoms from multiple
sclerosis (“MS”) and is to be used as an adjunct to a supervised
therapeutic exercise program in patients 22 years of age and over
by prescription only. Helius is advancing PoNS post-approval
research in MS through a recently launched Therapeutic Experience
Program (TEP) designed to partner with neurologists and
neurorehabilitation therapists at 10-12 US centers of excellence,
who express an interest in becoming “early adopters” of PoNS
therapy.
PoNS is also authorized for sale in Canada for two indications:
(i) for use as a short-term treatment (14 weeks) of chronic balance
deficit due to mild-to-moderate traumatic brain injury (“mmTBI”)
and is to be used in conjunction with physical therapy; and (ii)
for use as a short term treatment (14 weeks) of gait deficit due to
mild and moderate symptoms from MS and is to be used in conjunction
with physical therapy. PoNS is also authorized for sale in
Australia for short term use by healthcare professionals as an
adjunct to a therapeutic exercise program to improve balance and
gait.
Cautionary Disclaimer Statement
Certain statements in this news release are not based on
historical facts and constitute forward-looking statements or
forward-looking information within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and Canadian securities
laws. All statements other than statements of historical fact
included in this news release are forward-looking statements that
involve risks and uncertainties. Forward-looking statements are
often identified by terms such as “believe,” “expect,” “continue,”
“will,” “goal,” “aim” and similar expressions. Such forward-looking
statements include, among others, the scope and success of TEP, and
rate of adoption of PoNS Therapy.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those expressed or implied by such statements.
Important factors that could cause actual results to differ
materially from the Company’s expectations include uncertainties
associated with the Company’s capital requirements to achieve its
business objectives, and ability to raise capital, the impact of
the COVID-19 pandemic, the Company’s ability to train physical
therapists in the supervision of the use of the PoNS Therapy, the
Company’s ability to secure contracts with rehabilitation clinics,
the Company’s ability to obtain national Medicare coverage and to
obtain a reimbursement code so that the PoNS device is covered by
Medicare and Medicaid, the Company’s ability to build internal
commercial infrastructure, secure state distribution licenses,
build a commercial team and build relationships with Key Opinion
Leaders, neurology experts and neurorehabilitation centers, market
awareness of the PoNS device, future clinical trials and the
clinical development process, manufacturing and supply chain risks,
the product development process and FDA regulatory submission
review and approval process, other development activities, ongoing
government regulation, and other risks detailed from time to time
in the “Risk Factors” section of the Company’s Annual Report on
Form 10-K for the year ended December 31, 2021, and its other
filings with the United States Securities and Exchange Commission
and the Canadian securities regulators, which can be obtained from
either at www.sec.gov or www.sedar.com.
The reader is cautioned not to place undue reliance on any
forward-looking statement. The forward-looking statements contained
in this news release are made as of the date of this news release
and the Company assumes no obligation to update any forward-looking
statement or to update the reasons why actual results could differ
from such statements except to the extent required by law.
Investor Relations ContactLisa M. Wilson,
In-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Apr 2023 to Apr 2024